Acrivon Therapeutics (ACRV) Institutional Ownership $1.27 0.00 (0.00%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Acrivon Therapeutics (NASDAQ:ACRV)CurrentInstitutional OwnershipPercentage71.62%Number ofInstitutional Buyers(last 12 months)21TotalInstitutional Inflows(last 12 months)$23.26MNumber ofInstitutional Sellers(last 12 months)13TotalInstitutional Outflows(last 12 months)$2.75M Get ACRV Insider Trade Alerts Want to know when executives and insiders are buying or selling Acrivon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ACRV Institutional Buying and Selling by Quarter Acrivon Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025 Goldman Sachs Group Inc.57,519$117K0.0%-75.8%0.183% 5/15/2025 Baker BROS. Advisors LP22,809$46K0.0%-56.9%0.073% 5/13/2025 Wealthedge Investment Advisors LLC56,467$115K0.1%+420.1%0.180% 5/12/2025 Nuveen LLC13,402$27K0.0%N/A0.043% 5/12/2025 Invesco Ltd.35,315$72K0.0%N/A0.113% 3/12/2025 Wealthedge Investment Advisors LLC10,857$65K0.0%N/A0.035% 2/17/2025Nuveen Asset Management LLC13,402$81K0.0%-48.0%0.043% 2/17/2025 OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC102,784$619K0.0%+29.7%0.330% 2/17/2025 Corton Capital Inc.12,159$73K0.0%N/A0.039% 2/17/2025 Bridgeway Capital Management LLC74,600$449K0.0%-3.1%0.240% Get the Latest News and Ratings for ACRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025 Citadel Advisors LLC2,119,646$12.76M0.0%-1.0%6.807% 2/17/2025 Acorn Capital Advisors LLC405,237$2.44M1.3%N/A1.301% 2/14/2025 Northern Trust Corp117,323$706K0.0%+11.3%0.377% 2/14/2025 Dimensional Fund Advisors LP37,063$223K0.0%+20.2%0.119% 2/13/2025 Marshall Wace LLP597,794$3.60M0.0%-26.2%1.920% 2/13/2025 Barclays PLC38,091$228K0.0%+14.4%0.122% 2/13/2025 Renaissance Technologies LLC49,400$297K0.0%+7.6%0.159% 2/12/2025 Trexquant Investment LP16,871$102K0.0%-44.5%0.054% 2/12/2025 JPMorgan Chase & Co.25,809$155K0.0%-24.1%0.083% 2/11/2025 American Century Companies Inc.17,588$106K0.0%+14.2%0.056% 2/6/2025 Charles Schwab Investment Management Inc.113,840$685K0.0%-2.1%0.366% 2/4/2025 Bank of New York Mellon Corp27,635$166K0.0%-6.4%0.089% 1/24/2025 China Universal Asset Management Co. Ltd.6,602$40K0.0%N/A0.021% 12/26/2024 JPMorgan Chase & Co.33,991$238K0.0%+548.3%0.109% 12/13/2024 Exome Asset Management LLC116,757$817K0.5%N/A0.375% 11/19/2024 Barclays PLC33,306$233K0.0%+51.2%0.107% 11/16/2024 Geode Capital Management LLC302,103$2.12M0.0%-2.0%0.975% 11/15/2024 Barclays PLC33,306$233K0.0%+51.2%0.108% 11/15/2024 State Street Corp225,896$1.58M0.0%+26.4%0.729% 11/12/2024 Charles Schwab Investment Management Inc.116,253$814K0.0%-19.2%0.375% 10/10/2024 Exchange Traded Concepts LLC20,348$142K0.0%-52.5%0.066% 8/16/2024 Perceptive Advisors LLC5,360,858$31.09M0.7%+78.2%17.362% 8/14/2024 Marshall Wace LLP948,866$5.50M0.0%+58.8%3.073% 8/13/2024 Sands Capital Ventures LLC2,122,605$12.31M4.1%+28.4%6.874% 8/12/2024 XTX Topco Ltd10,493$61K0.0%N/A0.034% 8/9/2024 Renaissance Technologies LLC54,500$316K0.0%-46.9%0.177% 8/9/2024 Dimensional Fund Advisors LP10,066$58K0.0%N/A0.033% 8/1/2024 Rhumbline Advisers16,209$94K0.0%+48.9%0.052% 7/26/2024 Bank of New York Mellon Corp36,632$212K0.0%+50.1%0.119% 5/15/2024 Baker BROS. Advisors LP52,885$378K0.0%N/A0.234% Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again.5/14/2024 American International Group Inc.6,016$43K0.0%+39.2%0.027% 5/10/2024 Vanguard Group Inc.507,185$3.63M0.0%+6.6%2.241% 1/5/2024 Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060% 11/13/2023 Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020% 9/21/2023 Barclays PLC14,263$184K0.0%-16.0%0.065% 8/10/2023 AAF Wealth Management LLC10,678$138K0.1%N/A0.049% 7/20/2023 Exchange Traded Concepts LLC11,709$152K0.0%N/A0.053% 5/8/2023 Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798% 2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360% 2/14/2023 RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028% 2/13/2023 Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913% 2/10/2023 NEA Management Company LLC481,677$4.44M0.2%N/A2.306% 2/1/2023 Bank of Montreal Can42,444$545K0.0%N/A0.203% (Data available from 1/1/2016 forward) ACRV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACRV shares? During the previous two years, 34 institutional investors and hedge funds held shares of Acrivon Therapeutics. The most heavily invested institutionals were Perceptive Advisors LLC ($31.09M), Citadel Advisors LLC ($12.76M), Sands Capital Ventures LLC ($12.31M), Vanguard Group Inc. ($3.63M), Marshall Wace LLP ($3.60M), Acorn Capital Advisors LLC ($2.44M), and Federated Hermes Inc. ($2.16M).Learn more on ACRV's institutional investors. What percentage of Acrivon Therapeutics stock is owned by institutional investors? 71.62% of Acrivon Therapeutics stock is owned by institutional investors. Learn more on ACRV's institutional investor holdings. Which institutional investors have been buying Acrivon Therapeutics stock? Of the 26 institutional investors that purchased Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Perceptive Advisors LLC ($2.35M), Sands Capital Ventures LLC ($470K), Acorn Capital Advisors LLC ($405.24K), Marshall Wace LLP ($351.40K), Exome Asset Management LLC ($116.76K), Wealthedge Investment Advisors LLC ($56.47K), and Baker BROS. Advisors LP ($52.89K). How much institutional buying is happening at Acrivon Therapeutics? Institutional investors have bought a total of 4,120,676 shares in the last 24 months. This purchase volume represents approximately $24.18M in transactions. Which Acrivon Therapeutics major shareholders have been selling company stock? Of the 15 institutional investors that sold Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Marshall Wace LLP ($212.07K), Goldman Sachs Group Inc. ($180.03K), Federated Hermes Inc. ($78.04K), Renaissance Technologies LLC ($48.10K), Charles Schwab Investment Management Inc. ($30.12K), Baker BROS. Advisors LP ($30.08K), and Exchange Traded Concepts LLC ($22.52K). How much institutional selling is happening at Acrivon Therapeutics? Institutional investors have sold a total of 669,262 shares in the last 24 months. This volume of shares sold represents approximately $3.53M in transactions. Related Companies Enanta Pharmaceuticals Institutional Ownership Silence Therapeutics Institutional Ownership RAPT Therapeutics Institutional Ownership LifeVantage Institutional Ownership Molecular Partners Institutional Ownership SELLAS Life Sciences Group Institutional Ownership Spero Therapeutics Institutional Ownership Compugen Institutional Ownership Alpha Cognition Institutional Ownership Kyverna Therapeutics Institutional Ownership This page (NASDAQ:ACRV) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
